|Stress urinary incontinence (SUI) is characterized by the involuntary loss of urine due to a sudden increase in intra-abdominal pressure (eg from coughing, sneezing or exercise). Inhibition of serotonin and noradrenaline reuptake (SNRI) has been shown to be an attractive dual pharmacology mechanism for the treatment of SUI.|
This presentation will highlight the SNRI medicinal chemistry program at Pfizer including optimization of potency, selectivity, P450 inhibition, CPY2D6 metabolism and pharmacokinetics, which led to the identification of the SNRI clinical development candidate PF-184298.
The detailed in vitro, in vivo and human pharmacokinetic profile of PF-184298 will be presented.
First Time Disclosure of Clinical Candidates
1:30 PM-5:30 PM, Sunday, March 25, 2007 McCormick Place Lakeside -- Room E353 A/B, Level 3, Oral